J&J combo signals new era in EGFR lung cancer with survival win against AstraZeneca’s Tagrisso

New Era in EGFR Lung Cancer Treatment

Significant Survival Benefit

Johnson & Johnson's combination of RYBREVANT (amivantamab) and LAZCLUZE (lazertinib) has demonstrated a significant overall survival benefit compared to AstraZeneca's Tagrisso (osimertinib) in patients with EGFR-mutated non-small cell lung cancer (NSCLC)1 19. Key findings from the Phase 3 MARIPOSA study include:

The combination reduced the risk of death by 25% versus Tagrisso1
Median overall survival is projected to exceed one year beyond Tagrisso's median of 36.7 months1 19
At 3 years, 60% of patients on the combination were alive, compared to 51% on Tagrisso1

Unprecedented Results

This marks the first time a treatment has shown a statistically significant and clinically meaningful overall survival improvement over Tagrisso, the current standard of care19. The survival benefit started showing around 10 months after treatment and continued to widen over time1.

Impact on Treatment Landscape

These results signal a potential shift in the treatment paradigm for EGFR-mutated NSCLC:

The combination may replace Tagrisso as the new standard first-line treatment1
It offers a chemotherapy-free option that could delay the need for chemotherapy9
The data provide hope for improved long-term outcomes, as currently less than 20% of patients survive beyond 5 years9

Additional Benefits

The RYBREVANT-LAZCLUZE combination also showed improvements in other key measures:

Prolonged time to symptomatic progression by over 14 months compared to Tagrisso9
Demonstrated benefits in intracranial progression-free survival and response rates9

Looking Ahead

While these results are promising, experts note that longer-term overall survival data will be crucial in determining the best treatment choices for individual patients11. The oncology community is optimistic that this combination therapy could significantly improve outcomes for patients with EGFR-mutated NSCLC.

Sources:

1. https://www.fiercepharma.com/pharma/jj-combo-signals-new-era-egfr-lung-cancer-survival-win-against-astrazenecas-tagrisso

9. https://innovativemedicine.jnj.com/emea/rybrevant-amivantamab-plus-lazcluze-lazertinib-demonstrates-significant-overall-survival-benefit-in-patients-with-egfr-mutated-advanced-non-small-cell-lung-cancer-versus-osimertinib

11. https://www.cancernetwork.com/view/frontline-treatment-options-in-egfr-mutated-nsclc-show-promise

19. https://www.jnj.com/media-center/press-releases/rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-outperforms-osimertinib-with-a-significant-and-unprecedented-overall-survival-benefit-in-patients-with-egfr-mutated-non-small-cell-lung-cancer